Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
”In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding․
4 clinical predictors were significantly associated with increased CRB risk:
- anaemia and/or
- thrombocytopenia,
- age ≥75, PE as the index event,
- male sex (The Lancet Haematology)․
The accumulation of bleeding risk predictors emerged as a major determinant of clinically relevant bleeding, with consistent patterns across dosing regimens. (The Lancet Haematology)․
In patients with bleeding risk predictors, a lower clinically relevant bleeding with reduced-dose apixaban was observed.
Those data reinforce the clinical relevance of the API-CAT findings, including for patients with non-modifiable bleeding risk factors․
Please read our reply just published in The Lancet Haematology!”
Title 1: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez
Read the Full Article on The New England Journal of Medicine․
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology․
Title 3: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology․
Stay updated on all scientific advances with Hemostasis Today.
-
May 1, 2026, 17:55Salih Ehsan: The Deceptive Nature of B12 Deficiency Not Just Anemia
-
May 1, 2026, 17:45Angela Blue: Insurance Education as a Tool for Strengthening Patient Communities
-
May 1, 2026, 17:36Smitirupa Mishra: Hematology Formulas Made Simple, Structured, And Useful For Everyday Clinical Practice
-
May 1, 2026, 17:00Frank Weinz: VTE Prevention Strategies and Advances in Clinical Practice
-
May 1, 2026, 16:54Pierre François Sabouret: Women’s Health Should Be a Priority for All HCPs, Not Just WIC
-
May 1, 2026, 16:44Jean Jacques Kiladjian: A Global Triumph in MPN Research at ESHMPN 2026
-
May 1, 2026, 16:36Shek Sady Khan: VTE as a Major Yet Underrecognized Cause of Preventable Morbidity and Mortality
-
May 1, 2026, 16:11Anu Thomas: History of Blood Transfusion
-
May 1, 2026, 16:01A 100-Study Systematic Review Reevaluates PT and aPTT Testing in Perioperative Bleeding – JTH